blog

How Combining Binding Protein Data With Hormone Screenings Improves Diagnostic Accuracy

Understand total testosterone, free testosterone and SHBG, including EAU thresholds, symptoms, testing methods and questions for your clinician.

How Combining Binding Protein Data With Hormone Screenings Improves Diagnostic Accuracy
Share
PinterestFacebookLinkedInRedditTelegramX (Twitter)
Nov 12, 2026
Body, Libido & Performance

Total testosterone is the overall amount of testosterone measured in blood. Free testosterone is the portion not attached to blood proteins. SHBG stands for sex hormone-binding globulin, a protein that binds testosterone and helps explain the relationship between those measurements.

These results answer related but different questions. Total testosterone measures the overall circulating amount. Free testosterone assesses the unbound portion. SHBG adds context when the total result may not describe the free-testosterone picture clearly.

The European Association of Urology (EAU) uses total testosterone as the usual starting test in its guidance on late-onset hypogonadism. It recommends adding SHBG and calculated free testosterone when conditions that alter SHBG are present. Understanding how binding shapes a hormone report helps explain why these measurements belong together rather than in competition.

This article is educational rather than medical advice

This article is for informational purposes and is not medical advice. It does not diagnose testosterone deficiency or establish whether treatment is appropriate. Personal decisions about testing and care belong with a qualified clinician who can assess the full medical picture.

Clinical thresholds need symptoms and reliable measurements

A diagnostic threshold is not the same as a complete reference range. The EAU values below are clinical decision points for suspected late-onset hypogonadism. They should not be treated as universal lower and upper limits for total testosterone, free testosterone or SHBG.

Biologically, the measurements describe different things: overall testosterone concentration, its unbound portion and a binding protein. A cutoff for one cannot be applied to another.

Total testosterone is the starting measurement

The EAU identifies 12 nmol/L (3.5 ng/mL) as a potential diagnostic threshold for late-onset hypogonadism when compatible symptoms are present. This is a threshold for clinical assessment rather than a personal target.

Under this guidance, diagnosis requires relevant symptoms or signs alongside low morning testosterone confirmed on at least two occasions. Testing should use a reliable assay and fasting samples. A single low result therefore does not complete the diagnostic process.

The threshold helps organize the assessment. It does not explain why testosterone is low or establish that every reported symptom has a hormonal cause.

Calculated free testosterone has a separate threshold

For calculated free testosterone, the EAU says limited evidence supports 220 pmol/L (6.4 ng/dL) as a potentially reliable threshold in the relevant clinical setting. That qualification matters: the number is not a universal verdict for every man or every testing method.

Free testosterone is particularly useful when total testosterone leaves uncertainty and SHBG may be altered. The guideline says assessment can improve diagnostic accuracy in symptomatic men, especially older men with obesity.

The practical distinction is that free testosterone adds information to the assessment. It does not automatically replace total testosterone as the starting measurement.

SHBG provides context rather than a testosterone cutoff

The EAU approach uses SHBG to help interpret total testosterone and calculate free testosterone when indicated. SHBG is a binding protein measurement, not another version of the testosterone concentration.

The useful discussion is how the SHBG result fits the laboratory report and medical history. Applying the total testosterone or free testosterone thresholds above to SHBG would mix up different measurements.

When SHBG is altered, the guideline supports considering the wider panel instead of treating total testosterone as a complete assessment on its own.

The laboratory method affects interpretation

The EAU identifies equilibrium dialysis as the most accurate method for measuring free testosterone. Calculating free testosterone from total testosterone, SHBG and albumin is an alternative. The guideline advises against available direct free testosterone immunoassays because they do not provide an accurate estimate.

That warning is specific to free testosterone testing. For total testosterone, the guideline notes that standardized automated immunoassays correlate well with LC-MS/MS. It identifies LC-MS/MS as the most accurate method for sex-steroid evaluation.

A report labelled “free testosterone” therefore needs a method attached to it. Testostra’s explanation of the laboratory methods behind free testosterone results provides additional context for that discussion.

Sexual symptoms are more specific than general tiredness

The EAU describes sexual symptoms as more specific for late-onset hypogonadism than many general physical or psychological complaints. These include:

  • Reduced libido.
  • Erectile dysfunction.
  • Fewer spontaneous or morning erections.

The guideline also lists fatigue and low mood. Reduced energy, sleep disturbance and reduced strength can occur as well.

These symptoms are not exclusive to testosterone deficiency. Their presence needs cautious interpretation alongside the examination and biochemical findings. The symptom patterns discussed here concern suspected deficiency rather than serving as a checklist for high testosterone or an isolated SHBG abnormality.

Symptoms with normal or borderline total testosterone need context

A man may have symptoms while total testosterone appears normal or borderline. Under EAU guidance, the next question is whether conditions that alter SHBG make free testosterone assessment useful.

This is not a contest between the symptoms and the laboratory result. The clinical task is to assess whether the measurements explain the concern and whether other causes need investigation.

Low total testosterone without symptoms is a different situation

A low total testosterone result without compatible symptoms is not enough to diagnose late-onset hypogonadism under this guidance. The required combination is clinical evidence and confirmed biochemical evidence.

Likewise, symptoms do not establish the reason for an altered SHBG result. Bringing the symptom history and the full report to the same discussion is more useful than trying to interpret each flagged value separately.

Health conditions and sampling conditions influence the numbers

The EAU lists several factors associated with altered SHBG. These associations help clinicians decide when total testosterone may need additional context. They do not mean that one condition determines a man's entire hormone profile.

Several factors are associated with higher SHBG

The guideline lists:

  • Ageing.
  • Hepatic disease, meaning liver disease.
  • Hyperthyroidism, meaning an overactive thyroid.
  • HIV.
  • Smoking.
  • Some drugs and oestrogens.

These factors are relevant because circulating SHBG can affect total testosterone values. The clinical question is whether the binding-protein change makes the total result harder to interpret and supports assessing free testosterone.

Metabolic and thyroid conditions are associated with lower SHBG

The EAU lists the following among factors associated with lower SHBG:

  • Obesity.
  • Insulin resistance.
  • Hypothyroidism, meaning an underactive thyroid.
  • Some drugs.

For this reason, a medication list and relevant medical history are part of interpreting the panel. A total testosterone value considered without that context may leave an important part of the picture unresolved.

The guideline also recommends reviewing diseases, drugs and substances that can interfere with testosterone production or action. The review is broader than SHBG alone.

Timing and fasting status affect the testing context

The EAU recommends morning testosterone testing between 07:00 and 10:00, in a fasting state. It also recommends repeating a pathological initial measurement before testosterone therapy is started.

The guideline reports that total and calculated free testosterone can decrease after oral glucose administration. It cites evidence that non-fasting testing can underestimate total testosterone by more than 30%. That finding is not a correction factor to apply to an individual result.

The practical question is whether the sampling conditions were suitable for the intended assessment. When results appear inconsistent, the timing of the blood draw and fasting status belong in the review alongside the numbers themselves.

This makes the circumstances of the test part of the interpretation. It does not establish that changing a particular food will resolve testosterone-related symptoms.

Related hormones help investigate the cause

The EAU recommends LH and FSH testing to help distinguish types of hypogonadism. These results address a different question from SHBG: they contribute to investigating the hormonal pattern behind low testosterone.

The guideline describes functional hypogonadism as a diagnosis of exclusion after organic causes have been ruled out. In other words, identifying a low testosterone concentration is not the same as identifying its cause.

Understanding how clinicians read testosterone alongside LH and FSH can help prepare for that part of the conversation. The useful endpoint is an explanation that connects symptoms with confirmed measurements and relevant health factors.

A focused discussion brings the results together

“Were my testosterone samples taken under suitable conditions and has a low result been confirmed? Do my symptoms fit the results? Would SHBG and a reliable free testosterone assessment clarify the picture? Should we review my medicines, other health conditions and LH or FSH?”

How Testostra helps

Responsibility for interpreting a mixed testosterone panel stays with the treating doctor, while Testostra explains the hormone evidence in accessible language. Its coverage addresses the difficulty of distinguishing total testosterone from free testosterone and SHBG, giving men a clearer basis for discussing results without turning educational material into a personal treatment plan.

Read Resources

Sources

  1. Male Hypogonadism - EAU Guidelines on Sexual and Reproductive Health - Uroweb

Continue reading

Distinguishing Functional Hormone Suppression from Gland Disease in Clinical Care
November 17, 2026
TRT & Emerging Research

Distinguishing Functional Hormone Suppression from Gland Disease in Clinical Care

Read Article
Why Clinicians Look Past Single Lab Results to Build a Complete Picture of Patient Health
November 17, 2026
Low Testosterone

Why Clinicians Look Past Single Lab Results to Build a Complete Picture of Patient Health

Read Article
Short-Term Hormone Surges During Exercise and the Evidence on Muscle Growth and Strength
November 17, 2026
Lifestyle & Natural Support

Short-Term Hormone Surges During Exercise and the Evidence on Muscle Growth and Strength

Read Article
Man walking outdoors after exercise in a green urban setting.
GET IN TOUCH

Have a testosterone question or research topic in mind?

Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.

Contact Testostra